Why are we failing to address the issue of access to insulin? A national and global perspective

Diabetes Care

Volumn 41, Issue 6, 2018, Pages 1125-1131

  Beran, David ^a   Hirsch, Irl B ^b   Yudkin, John S ^c  

^a UNIVERSITY OF GENEVA   (Switzerland)

^b UNIVERSITY OF WASHINGTON   (United States)

^c UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

INSULIN;

DIABETES MELLITUS; ECONOMIC ASPECT; GOVERNMENT; GOVERNMENT REGULATION; HEALTH CARE ACCESS; HEALTH CARE DELIVERY; HEALTH CARE ORGANIZATION; HEALTH CARE UTILIZATION; HEALTH INSURANCE; HUMAN; INVESTMENT; PLURAL SECTOR; PRIVATE SECTOR; REVIEW; UNITED STATES; ADULT; AFRICA SOUTH OF THE SAHARA; CHILD; DEVELOPING COUNTRY; DRUG COST; ECONOMICS; EPIDEMIOLOGY; FINANCIAL MANAGEMENT; GLOBAL HEALTH; HEALTH CARE DISPARITY; INCOME; INSULIN DEPENDENT DIABETES MELLITUS; PUBLIC SECTOR; STATISTICS AND NUMERICAL DATA; TRENDS;

ADULT; AFRICA SOUTH OF THE SAHARA; CHILD; DEVELOPING COUNTRIES; DIABETES MELLITUS, TYPE 1; DRUG COSTS; FINANCING, GOVERNMENT; GLOBAL HEALTH; HEALTH SERVICES ACCESSIBILITY; HEALTHCARE DISPARITIES; HUMANS; INCOME; INSULIN; PRIVATE SECTOR; PUBLIC SECTOR; UNITED STATES;

EID: 85047479444     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc17-2123     Document Type: Review

References (107)

1. Beran D, Ewen M, Laing R. Constraints and challenges in access to insulin: A global perspective. Lancet Diabetes Endocrinol 2016;4:275-285
2. Seyoum B, Berhanu P. Profile of diabetic ketoacidosis in a predominantlyAfrican American urban patient population. Ethn Dis 2007;17:234-237
3. Randall L, Begovic J, Hudson M, et al. Recurrent diabetic ketoacidosis in inner-cityminority patients: Behavioral, socioeconomic, and psychosocial factors. Diabetes Care 2011;34:1891-1896
4. Gale EA. Dying of diabetes. Lancet 2006;368: 1626-1628
5. Beran D, Yudkin JS. Diabetes care in sub-Saharan Africa. Lancet 2006;368:1689-1695
6. Dieleman JL, Baral R, Birger M, et al. US spending on personal health care and public health, 1996-2013. JAMA 2016;316:2627-2646
7. Lipska KJ, Ross JS, Van Houten HK, Beran D, Yudkin JS, Shah ND. Use and out-of-pocket costs of insulin for type 2 diabetes mellitus from 2000 through 2010. JAMA 2014;311:2331-2333
8. Luo J, Avorn J, Kesselheim AS. Trends in Medicaid reimbursements for insulin from1991 through 2014. JAMA Intern Med 2015;175:1681-1686
9. The Express Scripts Lab. Express Scripts 2015 Drug Trend Report. St. Louis, MO, Express Scripts, 2016
10. Mintzberg H. Rebalancing Society. Oakland, CA, Berrett-Koehler Publishers, Inc., 2015
11. Ramiah I, ReichMR. Building effective publicprivate partnerships: Experiences and lessons from the African Comprehensive HIV/AIDS Partnerships (ACHAP). Soc Sci Med 2006;63:397-408
12. Katz IT, Bassett IV, Wright AA. PEPFAR in transitiondimplications for HIV care in South Africa. N Engl J Med 2013;369:1385-1387
13. Bendavid E, Holmes CB, Bhattacharya J, Miller G. HIV development assistance and adult mortality in Africa. JAMA 2012;307:2060-2067
14. Frieden TR. Government's role in protecting health and safety. N Engl J Med 2013;368:1857-1859
15. WorldHealth Organization. WHO Global Health Expenditure Atlas. Geneva, World Health Organization, 2014
16. Meisler L. Americans die younger despite spending the most on health care [article online]. Bloomberg, 2 August 2017. Available from https:// www.bloomberg.com/graphics/2017-health-carespending/. Accessed 2 January 2018
17. Organisation for Economic Cooperation and Development (OECD). Society at a Glance 2011. Paris, OECD Publishing, 2011
18. Braveman PA, Cubbin C, Egerter S, Williams DR, Pamuk E. Socioeconomic disparities in health in the United States: what the patterns tell us. Am J Public Health 2010;100(Suppl. 1):S186-S196
19. Organisation for Economic Cooperation and Development (OECD). United States: Tackling High Inequalities. Creating Opportunities For All. Paris, OECD Publishing, 2014
20. United Nations General Assembly. Universal declaration of human rights. Paris, United Nations, 1948 (Part A of General Assembly resolution 217 [III])
21. Seuba X. A human rights approach to theWHO Model List of EssentialMedicines. BullWorld Health Organ 2006;84:405-407; discussion 408-411
22. Hogerzeil HV, Samson M, Casanovas JV, Rahmani-Ocora L. Is access to essentialmedicines as part of the fulfilment of the right to health enforceable through the courts?. Lancet 2006;368: 305-311
23. Nygren-Krug H, Hogerzeil HV. Human rights: A potentially powerful force for essential medicines. Bull World Health Organ 2006;84:410
24. Ross JS, Kesselheim AS. Prescription-drug couponsdno such thing as a free lunch. N Engl J Med 2013;369:1188-1189
25. EwenM, Joose HJ, Ashigbie P, Beran D, Laing R. Insulin Prices Profile. Amsterdam, Health Action International, 2016
26. Burstein HJ, Schrag D. Biosimilar therapy for ERBB2 (HER2)-positive breast cancer: Close enough?. JAMA 2017;317:30-32
27. Lapteva M, Singhal M, Kalia Y. Biosimilar Insulin Regulatory Profile. Amsterdam, Health Action International, 2017
28. Aronson JK, Ferner RE. How similar are biosimilars?. BMJ 2016;353:i2721
29. Bauchner H, Fontanarosa PB, Golub RM. Scientific evidence and financial obligations to ensure access to biosimilars for cancer treatment. JAMA 2017;317:33-34
30. Kesselheim AS, Avorn J, Sarpatwari A. The high cost of prescription drugs in the United States: Origins and prospects for reform. JAMA 2016;316: 858-871
31. Organisation for Economic Cooperation and Development (OECD). Pharmaceutical Pricing Policies in a Global Market. Paris, OECD Publishing, 2008
32. Boerma JT, Bryce J, Kinfu Y, Axelson H, Victora CG; Countdown 2008 Equity Analysis Group. Mind the gap: Equity and trends in coverage of maternal, newborn, and child health services in 54 Countdown countries. Lancet 2008;371: 1259-1267
33. Beran D, Yudkin JS. Looking beyond the issue of access to insulin: what is needed for proper diabetes care in resource poor settings. Diabetes Res Clin Pract 2010;88:217-221
34. United Nations. The Millennium Development Goals Report 2015. New York, United Nations, 2015
35. Fuster V, Vôute J. MDGs: Chronic diseases are not on the agenda. Lancet 2005;366:1512-1514
36. United Nations. Sustainable development goals [Internet], 2016. Available from http://www.un .org/sustainabledevelopment/sustainabledevelopment-goals/. Accessed 15 December 2016
37. UN General Assembly. Political declaration of the High-levelMeeting of the General Assembly on the Prevention and Control of Non-communicable Diseases. New York, United Nations General Assembly, 2012 (Annex to Resolution A/RES/66/2 adopted 19 September 2011)
38. World Health Organization. Global Action Plan for the Prevention and Control of Noncommunicable Diseases 2013-2020. Geneva, World Health Organization, 2013
39. Dieleman JL, Graves C, Johnson E, et al. Sources and focus of health development assistance, 1990-2014. JAMA 2015;313:2359-2368
40. World Health Organization. WHO Director-General addresses health promotion conference [article online], 2013. Available from http://www .who.int/dg/speeches/2013/health-promotion- 20130610/en/. Accessed 22 February 2016
41. Staton T. The top 15 pharma companies by 2014 revenue [article online]. FiercePharma, 2015. Available from http://www.fiercepharma.com/ special-report/top-15-pharma-companies-by-2014-revenue. Accessed 22 December 2016
42. European Federation of Pharmaceutical Industries and Associations (EFPIA). The Pharmaceutical Industry in Figures. Brussels, EFPIA, 2016
43. Wirtz V. Insulin Market Profile. Amsterdam, Health Action International, 2016
44. Rotenstein LS, Ran N, Shivers JP, YarchoanM, Close KL. Opportunities and challenges for biosimilars: what's on the horizon in the global insulin market?. Clin Diabetes 2012;30:138-150
45. Schultz K. The global diabetes care market. Novo Nordisk, 2011. Available fromhttps://www. yumpu.com/en/document/view/3266542/theglobal-diabetes-care-market-kare-schultz-novonordisk. Accessed 12 September 2017
46. Greene JA, Riggs KR. Why is there no generic insulin?. Historical origins of a modern problem. N Engl J Med 2015;372:1171-1175
47. Hua X, Carvalho N, TewM, Huang ES, Herman WH, Clarke P. Expenditures and prices of antihyperglycemic medications in the United States: 2002-2013. JAMA 2016;315:1400-1402
48. Tylee T, Hirsch IB. Costs associated with using different insulin preparations. JAMA 2015;314: 665-666
49. Kaplan W, Beall R. Insulin Patent Profile. Amsterdam, Health Action International, 2016
50. Luo J, Kesselheim AS. Evolution of insulin patents and market exclusivities in the USA. Lancet Diabetes Endocrinol 2015;3:835-837
51. Kessel M. Restoring the pharmaceutical industry's reputation. Nat Biotechnol 2014;32:983-990
52. Ferrer-Miralles N, Domingo-Espín J, Corchero JL, Vázquez E, Villaverde A. Microbial factories for recombinant pharmaceuticals. Microb Cell Fact 2009;8:17
53. Cone J. There is no such a thing as "free" vaccines: Why MSF rejected Pfizer's donation offer of pneumonia vaccines [article online]. The BMJ Opinion, 19 October 2016. Available from http:// blogs.bmj.com/bmj/2016/10/19/jason-cone-thereis-no-such-a-thing-as-free-vaccines-why-msf-rejectedpfizers-donation-offer-of-pneumonia-vaccines/. Accessed 21 October 2016
54. Choudhry NK, Lee JL, Agnew-Blais J, Corcoran C, Shrank WH. Drug company-sponsored patient assistance programs: A viable safety net?. Health Aff (Millwood) 2009;28:827-834
55. Access to Medicine Foundation. Access to Medicine Index 2016. Haarlem, the Netherlands, Access to Medicine Foundation, 2016
56. Perrin C, Ewen M, Beran D. The role of biosimilarmanufacturers in improving access to insulin globally. Lancet Diabetes Endocrinol 2017;5:578
57. U.S. Food and Drug Administration. FDA approves Basaglar, the first "follow-on" insulin glargine product to treat diabetes [article online], 16 December 2015. Silver Spring, MD, U.S. Food and Drug Administration. Available from https:// wayback.archive-it.org/7993/20170722061458/ http://www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/ucm477734.htm. Accessed 17 December 2016
58. Biocon. Biocon's insulin glargine launched in Japan [article online], 15 July 2016. Bangalore, India. Available from http://www.biocon.com/biocon- press-releases-150716.asp.Accessed22December 2016
59. U.S. Food and Drug Adminstration. Generic competition and drug prices [article online], 2015. Silver Spring, MD, U.S. Food andDrug Administration. Available from http://www.fda.gov/AboutFDA/ CentersOffices/OfficeofMedicalProductsandTobacco/ CDER/ucm129385.htm. Accessed 22 December 2016
60. Is there a cure for high drug prices?. [article online]. Consumer Reports, August 2016. Available fromhttp://www.consumerreports.org/drugs/curefor-high-drug-prices/. Accessed 22 December 2016
61. Lipska K. Break up the insulin racket. New York Times, 21 February 2016, p. SR5
62. Robbins R. The insulinmarket is heading for a shakeup. But patients may not benefit [article online]. Stat, 14 October 2016. Available from https://www.statnews.com/2016/10/14/insulinprices-generics/. Accessed 15 October 2016
63. Smith F. The quality of private pharmacy services in lowand middle-income countries: A systematic review. Pharm World Sci 2009;31:351-361
64. Cameron A, Ewen M, Ross-Degnan D, Ball D, Laing R. Medicine prices, availability, and affordability in 36 developing and middle-income countries: A secondary analysis. Lancet 2009;373:240-249
65. Hill S, KienyMP. Towards access 2030. Lancet 2017;389:341-343
66. Reuters. U.S. headwinds force change of CEO at Novo Nordisk [article online]. Fortune, 1 September 2016. Available from http://fortune.com/ 2016/09/01/novo-nordisk-ceo-retire-insulin/. Accessed 17 December 2016
67. Torsoli A. Sanofi U.S. sales executive leaves after insulin forecast [article online]. Bloomberg, 4 December 2014. Available from https://www.bloomberg.com/news/articles/2014-12-04/sanofi-diabetes-chief-said-to-leave-afterinsulin-forecast. Accessed 17 December 2016
68. American Diabetes Association. Our corporate supporters [Internet], 2017. Alexandria, VA, American Diabetes Association. Available from http://www.diabetes.org/about-us/corporatesupport/ our-corporate-supporters.html. Accessed 7 January 2017
69. International Diabetes Federation. Our partners [Internet], 2015. Brussels, International Diabetes Federation. Available from http://www .idf.org/partners/meet-our-partners. Accessed 7 January 2017
70. Beran D, Capewell S, de CourtenM, et al. The International Diabetes Federation: Losing its credibility by partnering with Nestlé?. Lancet 2012;380:805
71. International Diabetes Federation. Mission & strategy [Internet], 2015. Available from https:// www.idf.org/who-we-are/mission-strategy.html. Brussels, International Diabetes Federation. Accessed 7 January 2017
72. International Diabetes Federation. Strategic Implementation Plan 2016-17. Brussels, International Diabetes Federation, 2015
73. American Diabetes Association. Accessibility and affordability of diabetes medications [article online], 23 February 2016. Alexandria, VA, American Diabetes Association. Available from https://makeinsulinaffordable.org/statement/. Accessed 10 January 2017
74. JDRF. Research funding facts [article online], 2017. Available from http://jdrf.org/about-jdrf/ fact-sheets/research-funding-facts/. Accessed 10 July 2017
75. Pérez-Peña R. Beyond 'I'm a diabetic, ' little common ground.NewYork Times, 17May 2006, p. A1
76. JDRF. Achieving insulin access and innovation [article online], 2017. Available from http://www .jdrf.org/get-involved/jdrf-advocacy/insulin-access/ . Accessed 17 July 2017
77. Petrovski G, Zivkovic M, Stratrova SS. Social media and diabetes: Can Facebook and Skype improve glucose control in patients with type 1 diabetes on pump therapy?. One-year experience. Diabetes Care 2015;38:e51-e52
78. Hernandez M. Diabetes and social media: A prescription for patient engagement. Diabetes Management 2013;3:203-205
79. Greene JA, Choudhry NK, Kilabuk E, ShrankWH. Online social networking by patients with diabetes: A qualitative evaluation of communication with Facebook. J Gen Intern Med 2011;26:287-292
80. Ariza-Montes JA, Lucia-Casademunt AM. ICT Management in Non-Profit Organizations. Hershey, PA, IGI Global, 2014
81. Chokshi DA. Improving access tomedicines in poor countries: The role of universities. PLoS Med 2006;3:e136
82. Edney A. FDA targets insulin for increased competition to lower prices [article online]. Bloomberg, 15 December 2017. Available from https:// www.bloomberg.com/news/articles/2017-12-15/ fda-targets-insulin-for-increased-competition-tolower-prices. Accessed 2 January 2018
83. Song Z. Using Medicare pricesdtoward equity and affordability in the ACA marketplace. N Engl J Med 2017;377:2309-2311
84. International Diabetes Federation. IDF DiabetesAtlas. 8th ed. Brussels, International Diabetes Federation, 2017
85. Confino J. Unilever's Paul Polman: Challenging the corporate status quo [article online]. The Guardian, 24 April 2012. Available from https:// www.theguardian.com/sustainable-business/paulpolman-unilever-sustainable-living-plan. Accessed 18 December 2017
86. Borelli T. Unilever and the failure of corporate social responsibility [article online]. Forbes, 15 March 2017. Available from https:// www.forbes.com/sites/econostats/2017/03/15/ unilever-and-the-failure-of-corporate-socialresponsibility/. Accessed 18 December 2017
87. Manson K. Africa takes lead in mobile revolution [article online]. Financial Times, 14 March 2013. Available from https://www.ft.com/content/ 0846ab76-8c8d-11e2-8ee0-00144feabdc0. Accessed 18 December 2017
88. Prahalad CK, Hammond A. Serving theworld's poor, profitably. Harv Bus Rev 2002;80:48-57, 124
89. Smith PA. A do-it-yourself revolution in diabetes care [article online]. New York Times, 22 February 2016. Available from https://www.nytimes.com/ 2016/02/23/health/a-do-it-yourself-revolution-indiabetes-care.html. Accessed 18 December 2017
90. Achrol R, Kotler P. Marketing's lost frontier: The poor. Markets Globalization Dev Rev 2016;1:3
91. Beran D, Basey M, Wirtz V, Kaplan W, Atkinson M, Yudkin JS. On the road to the insulin centenary. Lancet 2012;380:1648
92. Feudtner C. Bittersweet: Diabetes, Insulin, and the Transformation of Illness. Chapel Hill, The University of North Carolina Press, 2003
93. Hagens Berman Sobol Shapiro LLP. Insulin manufacturers hit with class-action lawsuit over drug price inflation scheme and RICO violations -time to break up the insulin racket [article online], 30 January 2017. Available from https://www .hbsslaw.com/cases/insulin-overpricing/pressrelease/ insulin-overpricing-insulin-manufacturers-hit-withclass-action-lawsuit-over-drug-price-inflation-schemeand-rico-violations-time-to-break-up-the-insulinracket. Accessed 10 July 2017
94. Noon A. Nevada senate passes insulin-price bill tough on drugmakers [article online]. U.S. News & World Report, 19May 2017. Available fromhttps:// www.usnews.com/news/best-states/nevada/articles/ 2017-05-19/nevada-senate-passes-insulin-price-billtough-on-drugmakers. Accessed 10 July 2017
95. HirstM. Keep the fire burning. Diabetes Voice 2013;58:4
96. American Diabetes Association. American Diabetes Association thanks the 2016 Principal Officers and welcomes 2017 officers to national Board of Directors [article online], 2017. Alexandria, VA, American Diabetes Association. Available from http://www.diabetes.org/newsroom/ press-releases/2017/american-diabetes-2017-boardof-directors.html. Accessed 7 January 2017
97. Lipska KJ, Hirsch IB, Riddle MC. Human insulin for type 2 diabetes: An effective, less-expensive option. JAMA 2017;318:23-24
98. Persad GC, Emanuel EJ. The ethics of expanding access to cheaper, less effective treatments. Lancet 2016;388:932-934
99. World HealthOrganization. TheWorld Health Report 1999: Making a Difference. Geneva, World Health Organization, 1999
100. FDR Four Freedoms Park. FDR's Second Inaugural Address, January 20, 1937 [article online], 20 January 2014. Available from http://www .fdrfourfreedomspark.org/blog/2015/2/17/fdrssecond-inaugural-address-january-20-1937. Accessed 20 September 2017
101. Diabetes Canada. Approximate cost reference list for antihyperglycemic agents [Internet], March 2016. Available from http://guidelines .diabetes.ca/browse/appendices/appendix5-2016. Accessed 31 May 2017
102. National Agency for the Safety ofMedicines and Health Products. Base de données publique des médicaments [Internet], 2017. Available from http://base-donnees-publique.medicaments. gouv.fr/index.php-result [in French]. Accessed 31 May 2017
103. Ji-young S. Basaglar challenges Sanofi's insulin drug Lantus [article online]. The Investor, 17 April 2017. Available from http://m .theinvestor.co.kr/view.php?ud=20170414000728. Accessed 31 May 2017
104. Dental and Pharmaceutical Benefits Agency (TLV). Welcome to the TLV [article online], 2017. Available from https://www.tlv.se/beslut/sok/ lakemedel/ [in Swedish]. Accessed 31 May 2017
105. Spezialitätenliste [Internet], 2017. Available fromhttp://www.spezialitätenliste.ch [inGerman]. Accessed 31 May 2017
106. Taylor P. Lilly and Boehringer launch Lantus biosimilar in UK[article online]. PMLive, 26 August 2015. Available from http://www.pmlive.com/ pharma-news/lilly-and-boehringer-launch-lantus- biosimilar-in-uk-806879. Accessed 31 May 2017
107. Good Rx. Insulins [article online], 2017. Available from https://www.goodrx.com/insulins. Accessed 31 May 2017